INTERFERON IN THE TREATMENT OF WOMEN INFECTED WITH HIGH-RISK HUMAN PAPILLOMAVIRUS
Main Article Content
Abstract
Human papillomavirus (HPV) is the most common sexually transmitted infection worldwide. About 99 % of cervical cancer is caused by persistent infection with high-risk types of HPV. It can take over 10 years from the time of an initial human papillomavirus infection until a cervical cancer. In most cases, HPV infections are transient and go away within 1 year. There is evidence that cell mediated immune responses of the host, both systemic and local, are important determinants of the course of infection, thus, it is reasonable to use immunocorrective therapy. Many studies have demonstrated the effectiveness of interferon alpha in complex therapy of HPV infection.
The aim – to determine the efficacy of interferon alpha-2b in reducing the viral load of high-risk HPV among infected women of reproductive age.
Materials and methods. 60 high-risk HPV positive women were included in the study. Qualitative and quantitative determination of high-risk HPV (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59) was carried out by PCR in real time. Patients were randomized into two groups: group 1 (n = 30) received alfa-interferon in the form of rectal suppositories; group 2 (n = 30) did not receive the drug. Control study was conducted 1 month later. The average age in group 1 was 31,7 ± 1,6 years, in group 2 – 35,0 ± 1,6 years (p = 0,08). In group 1 monoinfection diagnosed in 72,4 % of cases, mixed infection in 27,6 % of cases in group 2 – at 64,3 % and 35,7 %, respectively.
Results. The average viral load was 3,5 ± 0,2 Lg (HPV on 105 cells) in group 1 and 3,4 ± 0,3 in group 2 (p = 0,473). Сlinically significant viral load dominated in group 1 (41,4 %), insignificant viral load was dominated in group 2 (42,9 %). After 1 month the average viral load was 1,9 ± 0,3 Lg (HPV on 105 cells) in group 1 and 2,8 ± 0,4 Lg in group 2 (р = 0,04). There were statistically significant difference in both groups before and after 1 month (p < 0,05). Elimination of HPV occurred in 34,5 % of cases in group 1 and at 28,6 % of cases in group 2. The viral load in the group that used interferon alfa-2b decreased by 45,5 %, in the comparison group only 18,3 %
Conclusion. The treatment with interferon alfa-2b is effective in reducing viral load in HPV infected women of reproductive age. Long-term follow-up observation of this cohort is needed and further study of effective treatment regimens. Long- follow-up observation of this cohort is needed, in order to assess whether this regimen is effective.
Keywords
Author Biographies
Кристина Владимировна Марочко,
postgraduate student, department of obstetrics and gynecology N 2Наталья Владимировна Артымук,
Artymuk Natalia Vladimirovna
MD, PhD, professor, deputy editor of the journal Mother and Baby in Kuzbass.
She is the Head of the Department of Obstetrics and Gynaecology №2, the Deputy Editor-in-Chief. She is also the President of the Kemerovo regional public organization “Association of obstetricians and gynecologists”, the chief obstetrician-gynecologist of the Siberian Federal district; the member of the Board of the Russian Society of Obstetricians and Gynaecologists, the member of the European Society of Contraception and Reproductive Health, the European Society of Gynaecological Oncology and the International Society of Gynecological Endocrinology.
She has graduated from Kemerovo State Medical institute with honors. She studied in clinical residency in obstetrics and gynecology at School of Arenberg (Salzburg, Austria) and School of Bloomberg (Johns Hopkins University, Baltimore, USA). One is a specialist in ultrasound diagnostics in obstetrics and gynecology, endocrinology and endoscopic surgery. In 1996 in Barnaul she defended her PhD thesis and her doctoral thesis in 2003 in Moscow.
Her priorities are: endocrine gynecology, infertility, cervix uteri pathology, menopausal disorders, disorder of menstrual function, endoscopic and abdominal gynecological surgery.
She deals with reproductive health problems, non-surgical and surgical treatment of benign neoplasms of genital organs. She is an author of more than 450 scientific works, including 3 monographs and study manuals for doctors. She has her highest medical qualification category in “Obstetrics and gynecology”.
Article Details
Information about financing and conflict of interests
The authors declare that they have no apparent or potential conflicts of interest related to the publication of this article.
This work is licensed under a Creative Commons Attribution 4.0 License.
How to Cite
References
Prilepskaya VN, Dovletkhanova ER, Abakarova PR. Possibilities of therapy for hpv-associated genital diseases in women. Obstetrics and Gynecology. 2011; (5): 123-128. Russian (Прилепская В.Н., Довлетханова Э.Р., Абакарова П.Р. Возможности терапии ВПЧ-ассоциированных заболеваний гениталий у женщин //Акушерство и гинекология. 2011. № 5. С. 123-128.)
De Vuyst H, Clifford G, Li N, Franceschi S. HPV infection in Europe. Eur. J. Cancer. 2009. V. 45, N 15. P. 2632-2639
Abramovskih OS., Dolgyshina VF., Telesheva LF, Letyaeva OI, Antimirova EA. Papillomavirus infection of the urogenital tract: epidemiological aspects (review). Gynecology. 2016; (2): 34-39. Russian (Абрамовских О.С., Долгушина В.Ф., Телешева Л.Ф., Летяева О.И., Антимирова Е.А. Папилломавирусная инфекция урогенитального тракта: эпидемиологические аспекты (обзор) //Гинекология. 2016. № 2. С. 34-39.)
Marochko KV. The sensitivity of distinct techniques for identification of cervical in-traepithelial neoplasia grade 3 and cervical cancer. Fundamental and Clinical Medicine. 2016; 1 (2): 51-55. Russian (Марочко К.В. Чувствительность методов исследования в выявлении цервикальной интраэпителиальной неоплазии 3 степени и рака шейки матки //Фундаментальная и клиническая медицина. 2016. Т. 1, № 2. С. 51-55.)
Artymuk NV, Marochko KV. The prevalence of human papillomavirus infection among female prisoners in Siberia. The Official Journal of the European Society of Contraception and Reproductive Health. Book of Abstracts. The 14th Congress – 2nd Global Conference of the European Society of Contraception and reproductive health Basel, Switzerland 4-7 May, 2016. P. 133
Serov VN, Tverdikova MA, Tjutjunnik VL. Genital HPV infection: the basic principles of treatment. Russkij medicinskij zhurnal. Mat' i ditja. Akusherstvo i ginekologija. 2010; (19): 1170-1174. Russian (Серов В.Н., Твердикова М.А., Тютюнник В.Л. Папилломавирусная инфекция гениталий: основные принципы лечения //РМЖ. Мать и дитя. Акушерство и гинекология. 2010. № 19. С. 1170-1174.)
Abramovskikh OS, Telesheva LF, Letyaeva OI, Savochkina AU, Orner IU, Baturina IL, Mezentseva EA. Immunological aspects of pathogenesis of human papillomavirus infection in the female reproductive tract. Immunopathology, Allergology, Infectology. 2012; (2): 95-101. Russian (Абрамовских О.С., Телешева Л.Ф., Летяева О.И., Савочкина А.Ю., Орнер И.Ю., Батурина И.Л., Мезенцева Е.А. Иммунологические аспекты патогенеза папилломавирусной инфекции репродуктивного тракта женщин //Иммунопатология, аллергология, инфектология. 2012. № 2. С. 95-101.)
Solovyev AM, Perlamutrov YuN, Korsunskaya IM.State of the immune system of patients with recurrent urogenital infections. Immunopathology, Allergology, Infectology. 2013; (4): 49-56. Russian (Соловьев А.М., Перламутров Ю.Н., Корсунская И.М. Состояние иммунной системы у больных рецидивирующими инфекциями урогенитального тракта //Иммунопатология, аллергология, инфектология. 2013. № 4. С. 49-56.)
Semenov DM. Immunological abnormalities in women infected with human papilloma virus. Immunopathology, Allergology, Infectology. 2016; (2): 67-73. Russian (Семенов, Д.М. Иммунологические изменения у женщин, инфицированных вирусом папилломы человека //Иммунопатология, аллергология, инфектология. 2016. № 2. С. 67-73.)
Zarochentseva NV, Malinovskaia VV, Torshina ZV. Specific features of immunomodulatory therapy in pregnant women with papillomavirus infection. Russian Bulletin of Obstetrician-Gynecologist. 2014; 14 (3): 57-63. Russian (Зароченцева Н.В., Малиновская В.В., Торшина З.В. Особенности иммунокорригирующей терапии у беременных с папилломавирусной инфекцией //Российский вестник акушера-гинеколога. 2014. Т. 14, № 3. С. 57-63.)
Venediktova MG, Dobrokhotova YE. Immunocorrecting drugs in a combination therapy of moderate and severe cervical epithelial dysplasia associated with HPV infection. Effective Pharmacotherapy. Obstetrics and Gynecology. 2015; (25): 38-41. Russian (Венедиктова М.Г., Доброхотова Ю.Э. Иммунокорригирующие препараты в комплексном лечении дисплазии эпителия шейки матки умеренной и тяжелой степени на фоне ВПЧ //Эффективная фармакотерапия. Акушерство и гинекология. 2015. № 25. С. 38-41.)
Petrunin D.D. Using preparations of interferon alpha for the treatment of urogenital infections. AG-info. 2009; (2): 6-12. Russian (Петрунин Д.Д. Использование препаратов интерферона альфа для лечения урогенитальных инфекций //АГ-инфо. 2009. № 2. С. 6-12.)
Prilepskaja V.N., Rogovskaja S.I., Bebneva T.N., Mezhevitinova E.A., Petrunin D.D. The use of interferon drugs in the treatment of squamous cervical intraepithelial lesions of low grade. AG-info. 2008; (3): 15-21. Russian (Прилепская В.Н., Роговская С.И., Бебнева Т.Н., Межевитинова Е.А., Петрунин Д.Д. Применение препаратов интерферона при лечении плоскоклеточных интраэпителиальных поражений шейки матки низкой степени //АГ-инфо. 2008. № 3. С. 15-21.)
Jach R, Basta A, Szczudrawa A. Role of immunomodulatory treatment with Iscador QuS and Intron A of women with CIN1 with concurrent HPV infection. Ginekol Pol. 2003; 74 (9): 729-735
Vergejchik GI. Features immunotherapy in the treatment of various forms of genital human papillomavirus infection. Prescription. 2011; (6): 126-134. Russian (Вергейчик Г.И. Возможности иммунотерапии в лечении различных форм генитальной папилломавирусной инфекции //Рецепт. 2011. № 6. С. 126-134.)
Beljakovskij VN, Al'-Jahiri OV, Al'-Jahiri AK. The process of elimination endovaginal interferon in the treatment of human papillomavirus infection. 2010; 1 (23): 139-142. Russian (Беляковский В.Н., Аль-Яхири О.В., Аль-Яхири А.К. Способ элиминационной эндовагинальной интерферонотерапии в лечении папилломавирусной инфекции //Проблемы здоровья и экологии. 2010. № 1 (23). С. 139-142.)
Zuykova IN, Shulzhenko AYe. Persistent human papillomavirus infection: cytokine dysbalance and treatment strategies. Effective Pharmacotherapy. Obstetrics and Gynecology. 2013; 2 (18): 54-61. Russian (Зуйкова И.Н., Шульженко А.Е. Персистирующая папилломавирусная инфекция: цитокиновый дисбаланс и подходы к терапии //Эффективная фармакотерапия. Акушерство и гинекология. 2013. Т. 2, № 18. С. 54-61.)